Pre-register biomarker validation studies the way trials are registered
Drug trials must be registered before they start so results cannot be hidden or reshaped. Studies that claim a biomarker predicts outcome should be registered too.
Biomarker studies suffer from selective reporting, flexible cut-points and unreported failed validations. A registry for biomarker validation studies (marker, assay, population, pre-specified analysis and cut-point, primary performance measure), required by journals for prognostic and predictive claims, would enable tracking of validation attempts including the negative ones, and reduce analytic flexibility.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
- Preclinical results do not reproduce · Fewer than half of landmark cancer biology findings reproduce when someone else tries.
Pages like this
not linked directly; found by shared links- IdeaTime-stamped electronic lab notebooks submitted with the paper
Shares Registered reports for cancer biology: the plan is peer-reviewed before the result, Preclinical results do not reproduce.
- IdeaEnforce individual participant data sharing as a condition of publication and funding
Shares ClinicalTrials.gov, Preclinical results do not reproduce.
- IdeaA public biomarker validation utility with pre-diagnostic biobanks and blinded testing
Shares Preclinical results do not reproduce, Biomarkers are not validated or standardised.
- IdeaHold organoid drug tests to the same standard as a diagnostic test
Shares Preclinical results do not reproduce, Biomarkers are not validated or standardised.